Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer (vol 9, 73, 2023)

被引：0

作者：

Fabi, Alessandra

Carbognin, Luisa

Botticelli, Andrea

Paris, Ida

Fuso, Paola

Savastano, Maria Cristina

La Verde, Nicla

Strina, Carla

Pedersini, Rebecca

Guarino, Stefania

Curigliano, Giuseppe

Criscitiello, Carmen

Raffaele, Mimma

Beano, Alessandra

Franco, Antonio

Valerio, Maria Rosaria

Verderame, Francesco

Fontana, Andrea

Haspinger, Eva Regina

Caldara, Alessia

Di Leone, Alba

Tortora, Giampaolo

Giannarelli, Diana

Scambia, Giovanni

机构：

[1] Fondazione Policlinico Universitario A. Gemelli IRCCS,Precision Medicine Unit in Senology

[2] Fondazione Policlinico Universitario A. Gemelli IRCCS,Division of Gynecology Oncology, Department of Woman and Child Health and Public Health

[3] University of Rome,Medical Oncology Unit, La Sapienza

[4] Medical Oncology Unit,Department of Oncology and Hemato

[5] A.O.U. San Giovanni di Dio e Ruggi D’Aragona,Oncology

[6] Medical Oncology Unit,Department of Medical Oncology1

[7] ASST Fatebenefratelli Sacco PO Luigi Sacco - Polo Universitario,Breast Unit, Department of Women, Children and Public Health Sciences

[8] Medical Oncology Unit Azienda Socio-Sanitaria Territoriale Cremona,Medical Oncology, Department of Translational Medicine and Surgery

[9] Medical Oncology Unit ASST Spedali Civili,Epidemiology and Biostatistics Facility

[10] Medical Oncology Unit Santa Maria della Misericordia Hospital,undefined

[11] University of Milan,undefined

[12] Division of Early Drug Development,undefined

[13] European Institute of Oncology,undefined

[14] IRCCS,undefined

[15] Presidio Cassia Sant’andrea,undefined

[16] Dipartimento Oncologico,undefined

[17] Asl Roma1,undefined

[18] Città della Salute e della Scienza Hospital,undefined

[19] Fondazione Policlinico Universitario Agostino Gemelli IRCCS,undefined

[20] Medical Oncology,undefined

[21] Policlinico Universitario P. Giaccone,undefined

[22] Medical Oncology,undefined

[23] AO Riuniti Villa Sofia,undefined

[24] Cervello,undefined

[25] Medical Oncology Unit 2,undefined

[26] Azienda Ospedaliero-Universitaria Pisana,undefined

[27] Azienda Sanitaria dell’Alto Adige – Ospedale di Merano,undefined

[28] Santa Chiara Hospital,undefined

[29] Medical Oncology,undefined

[30] Fondazione Policlinico Universitario A. Gemelli IRCCS,undefined

[31] Università Cattolica del Sacro Cuore,undefined

[32] Fondazione Policlinico Universitario A. Gemelli IRCCS,undefined

[33] Università Cattolica del Sacro Cuore,undefined

来源：

NPJ BREAST CANCER | 2024年 / 10卷 / 01期

关键词：

D O I：

10.1038/s41523-024-00619-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：1

共 50 条

[1] Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer
Fabi, Alessandra
Carbognin, Luisa
Botticelli, Andrea
Paris, Ida
Fuso, Paolo
Savastano, Maria Cristina
La Verde, Nicla
Strina, Carla
Pedersini, Rebecca
Guarino, Stefania
Curigliano, Giuseppe
Criscitiello, Carmen
Raffaele, Mimma
Beano, Alessandra
Franco, Antonio
Valerio, Maria Rosaria
Verderame, Francesco
Fontana, Andrea
Haspinger, Eva Regina
Caldara, Alessia
Di Leone, Alba
Tortora, Giampaolo
Giannarelli, Diana
Scambia, Giovanni
NPJ BREAST CANCER, 2023, 9 (01)
[2] Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer
Alessandra Fabi
Luisa Carbognin
Andrea Botticelli
Ida Paris
Paola Fuso
Maria Cristina Savastano
Nicla La Verde
Carla Strina
Rebecca Pedersini
Stefania Guarino
Giuseppe Curigliano
Carmen Criscitiello
Mimma Raffaele
Alessandra Beano
Antonio Franco
Maria Rosaria Valerio
Francesco Verderame
Andrea Fontana
Eva Regina Haspinger
Alessia Caldara
Alba Di Leone
Giampaolo Tortora
Diana Giannarelli
Giovanni Scambia
npj Breast Cancer, 9 (1)
[3] Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer
Alessandra Fabi
Luisa Carbognin
Andrea Botticelli
Ida Paris
Paolo Fuso
Maria Cristina Savastano
Nicla La Verde
Carla Strina
Rebecca Pedersini
Stefania Guarino
Giuseppe Curigliano
Carmen Criscitiello
Mimma Raffaele
Alessandra Beano
Antonio Franco
Maria Rosaria Valerio
Francesco Verderame
Andrea Fontana
Eva Regina Haspinger
Alessia Caldara
Alba Di Leone
Giampaolo Tortora
Diana Giannarelli
Giovanni Scambia
npj Breast Cancer, 9
[4] Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer
Alessandra Fabi
Luisa Carbognin
Andrea Botticelli
Ida Paris
Paola Fuso
Maria Cristina Savastano
Nicla La Verde
Carla Strina
Rebecca Pedersini
Stefania Guarino
Giuseppe Curigliano
Carmen Criscitiello
Mimma Raffaele
Alessandra Beano
Antonio Franco
Maria Rosaria Valerio
Francesco Verderame
Andrea Fontana
Eva Regina Haspinger
Alessia Caldara
Alba Di Leone
Giampaolo Tortora
Diana Giannarelli
Giovanni Scambia
npj Breast Cancer, 10
[5] Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions
Kagihara, Jodi A.
Andress, Michelle
Diamond, Jennifer R.
EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2020, 5 (02): : 59 - 65
[6] Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer
Huang, Min
Fasching, Peter
Haiderali, Amin
Pan, Wilbur
Gray, Emma
Zhou, Zheng-Yi
Hu, Peter
Chaudhuri, Mitashri
De Tilleghem, Celine Le Bailly
Cappoen, Nicolas
O'Shaughnessy, Joyce
IMMUNOTHERAPY, 2022, 14 (13) : 1027 - 1041
[7] Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer
Mavratzas, Athanasios
Seitz, Julia
Smetanay, Katharina
Schneeweiss, Andreas
Jaeger, Dirk
Fremd, Carlo
FUTURE ONCOLOGY, 2020, 16 (03) : 4439 - 4453
[8] Triple-negative first-line study: Neoadjuvant trial of nab-paclitaxel and atezolizumab, a PD-L1 inhibitor, in patients with triple negative breast cancer (TNBC) (NCT02530489)
Litton, J. K.
Moulder, S.
Helgason, T.
Clayborn, A. R.
Rauch, G. M.
Gilcrease, M.
Adrada, B. E.
Huo, L.
Hess, K. R.
Symmans, W. F.
Thompson, A.
Tripathy, D.
Mittendorf, E. A.
CANCER RESEARCH, 2017, 77
[9] First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment
Velcheti, Vamsidhar
Chandwani, Sheenu
Chen, Xin
Pietanza, M. Catherine
Burke, Thomas
IMMUNOTHERAPY, 2019, 11 (10) : 889 - 901
[10] First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer A Cost-Effectiveness Analysis
Weng, Xiuhua
Huang, Xiaoting
Li, Hongchao
Lin, Shen
Rao, Xin
Guo, Xianzhong
Huang, Pinfang
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2020, 43 (05): : 340 - 348

← 1 2 3 4 5 →